Securities code: Berry Genomics Co.Ltd(000710) securities abbreviation: Berry Genomics Co.Ltd(000710) Announcement No.: 2022026 Berry Genomics Co.Ltd(000710)
Announcement on abnormal fluctuations in stock trading
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Details of abnormal fluctuations in stock trading
Berry Genomics Co.Ltd(000710) (hereinafter referred to as “the company” and “the company”) has accumulated more than 20% deviation from the closing price on April 13, 2022 and April 14, 2022. According to the relevant provisions of the trading rules of Shenzhen Stock Exchange, it belongs to abnormal fluctuation of stock trading.
2、 Relevant information concerned and verified by the company
According to the requirements of relevant regulations, the company has conducted timely verification and inquired the controlling shareholder, actual controller and persons acting in concert of the company. The relevant verification is explained as follows:
1. The company does not need to amend the performance forecast disclosed in the previous period; Other information disclosed by the company in the early stage does not need to be corrected or supplemented. The information disclosed by the company does not contain other major information that may have a great impact on the trading price of the company’s shares.
2. The company, the controlling shareholder and the actual controller do not have any major events that affect the abnormal fluctuation of the company’s stock trading, nor do they have any major information related to the company that should be disclosed but not disclosed, or major events in the planning stage.
3. The company has not found any media reports or market rumors that need to be clarified or responded, and has not found any other major events that may have a great impact on the company’s stock trading price.
4. The company did not find that directors, supervisors, senior managers, controlling shareholders and persons acting in concert bought and sold the company’s shares during the abnormal fluctuation of the company’s shares.
3、 Whether there is a description of the information that should be disclosed but not disclosed
The board of directors of the company confirms that the company does not have any matters that should be disclosed but not disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange (revised in 2022), or planning, negotiation, intention, agreement, etc. related to such matters; The board of directors has not been informed that the company has undisclosed information that should be disclosed in accordance with the stock listing rules of Shenzhen Stock Exchange (revised in 2022) and has a great impact on the trading price of the company’s shares and their derivatives; The information disclosed by the company in the early stage does not need to be corrected or supplemented.
4、 Relevant risk tips
1. Through self-examination, the company does not violate the fair disclosure of information.
2. Securities times, China Securities News, Securities Daily, Shanghai Securities News and cninfo (www.cn. Info. Com. CN.) For the information disclosure media selected by the company, all information of the company shall be subject to the information published in the above designated media. Please pay attention to the investment risks.
It is hereby announced.
Berry Genomics Co.Ltd(000710) board of directors April 14, 2022
